Breast Cancer News and Research

Latest Breast Cancer News and Research

Syndax announces data from entinostat phase 2 study on HL

Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.

12 Dec 2011

Researchers shown how BRCA1 inactivation raises cancer risk

Working with human breast cells, researchers at the Johns Hopkins Kimmel Cancer Center have shown how the inactivation of a single copy of the breast cancer gene BRCA1 leaves breast cells vulnerable to cancer by reducing their ability to repair DNA damage, causing genetic instability.

12 Dec 2011

Obese women with early-stage HER2-positive breast cancer may have poorer outcomes

Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth.

12 Dec 2011

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.

12 Dec 2011

Many postmenopausal women quit breast cancer drugs early because of side effects

Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves -- as well as the largest, most scientifically rigorous study to examine the question -- reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.

12 Dec 2011

People in Northern Ireland less likely to develop cancers

People in Northern Ireland have a lower risk of developing some cancers than those living in the Republic of Ireland, according to the All-Ireland Cancer Atlas - a collaborative publication by the Northern Ireland Cancer Registry at Queen's University Belfast and the National Cancer Registry in Cork.

12 Dec 2011

Study describes miR-124 can prevent and treat liver cancer

Cancer of the liver - rare in the United States but the third-leading cause of cancer death worldwide - can result from environmental exposures or infections like chronic hepatitis, but the link is poorly understood.

12 Dec 2011

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Aeterna Zentaris Inc. today announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131.

11 Dec 2011

Breast cancer hope with new drug and new combination regimens

last week at the San Antonio Breast Cancer Symposium, researchers announced encouraging results from studies of two cancer medications that appeared to keep breast cancer from advancing.

11 Dec 2011

Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer

A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients.

9 Dec 2011

ZEN bust-enhancing supplements may increase risk of breast cancer

Women who use bust-enhancing dietary supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring toxin that widely contaminates agricultural products, could be increasing their risk of breast cancer. That is the warning from breast health experts in a paper published online ahead of print publication in the January issue of IJCP, the International Journal of Clinical Practice.

9 Dec 2011

Patients having stray tumor cells in the blood should receive aggressive treatment

The presence of circulating tumor cells in the blood appears to have no relationship to survival in women who have just been diagnosed with inflammatory breast cancer, according to new research from Fox Chase Cancer Center.

9 Dec 2011

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.

9 Dec 2011

Initial results from whole-genome sequencing trial for triple negative breast cancer

Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium.

9 Dec 2011

VDF, CDC and VDC to educate women about gender-specific DVT risks

Deep vein thrombosis (DVT) is a blood clot in the deep veins in the legs. These clots can break loose and travel to the lungs, causing a potentially fatal pulmonary embolism (PE). Even when they don't, they can cause permanent damage to the leg veins that results in long-term pain, swelling, and disability of the leg.

9 Dec 2011

Report uncovers disparities in cancer incidence and death rates in Australia

Over the past quarter century in Australia, cancer incidence rates have increased while deaths from cancer have steadily decreased. Those are some of the findings of a recent study published early online in the Asia-Pacific Journal of Clinical Oncology.

9 Dec 2011

MRI can predict breast cancer prognosis

Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients to appropriate therapies, according to preliminary data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

9 Dec 2011

Ovary removal in younger women may lead to low-bone mineral density, arthritis

Having both ovaries removed before age 45 is strongly associated with low-bone mineral density and arthritis in later years, according to a new study by Johns Hopkins oncologists and epidemiologists. The analysis covered several thousand women who took part in a U.S. government-sponsored, multiyear national health study, and excluded women whose ovaries were removed due to cancer.

9 Dec 2011

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

9 Dec 2011

Breast cancer risks and management updates

A new report that looks at the environmental factors that affect risk of breast cancer is out. It suggests that women can reduce their risk by avoiding unnecessary medical radiation, forgoing hormone treatments for menopause that combine estrogen and progestin, limiting alcohol intake and minimizing weight gain.

8 Dec 2011

Breast Cancer News and Research

Latest Breast Cancer News and Research

Syndax announces data from entinostat phase 2 study on HL

Researchers shown how BRCA1 inactivation raises cancer risk

Obese women with early-stage HER2-positive breast cancer may have poorer outcomes

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

Many postmenopausal women quit breast cancer drugs early because of side effects

People in Northern Ireland less likely to develop cancers

Study describes miR-124 can prevent and treat liver cancer

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Breast cancer hope with new drug and new combination regimens

Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer

ZEN bust-enhancing supplements may increase risk of breast cancer

Patients having stray tumor cells in the blood should receive aggressive treatment

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Initial results from whole-genome sequencing trial for triple negative breast cancer

VDF, CDC and VDC to educate women about gender-specific DVT risks

Report uncovers disparities in cancer incidence and death rates in Australia

MRI can predict breast cancer prognosis

Ovary removal in younger women may lead to low-bone mineral density, arthritis

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Breast cancer risks and management updates

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Breast Cancer News and Research

Latest Breast Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in